do_not_disturb_altRecruitment Complete

Symptomatic Transthyretin Amyloid Cardiomyopathy

Bayer Identifier:
ALXN2060-TAC-302
ClinicalTrials.gov Identifier:
NCT04622046
EudraCT Number:
Not Available
EU CT Number:
Not Available
A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A
    -
    -

Trial summary

Enrollment Goal
N/A
Trial Dates
November 2020 - September 2025
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Acoramidis (BAY3684938)
Accepts Healthy Volunteer
N/A

Trial design

A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A